Emerging therapy
BPC-157
BPC-157 is a synthetic peptide fragment with a large animal literature on tissue healing and one of the largest gaps between internet enthusiasm and human evidence anywhere in the longevity world. It is not a licensed medicine in any country, and the products sold online are unregulated grey-market chemicals labelled 'for research use'.
Quick verdict
A consistent rodent literature suggests accelerated healing of tendon, muscle and gut injuries. A 2025 systematic review of its orthopaedic use found no randomised human trial has ever been published. Every human-effectiveness and human-safety claim made for BPC-157 is currently unsupported.
The assessment
Claim by claim
Each claim is graded on its own evidence. A grade for one claim says nothing about the others.
| Claim | What was measured | Evidence |
|---|---|---|
| Accelerates tendon and soft-tissue healing | Physical function | Preclinical |
| Improves injury recovery in humans | Disease outcome | Insufficient |
Accelerates tendon and soft-tissue healing
Preclinical onlyOutcome measured: Physical function — A measured capability such as walking speed, grip strength or VO₂ max.
In rodents, this claim has real support: studies report faster histological and biomechanical recovery of injured tendon and muscle. In humans it has never been tested in a controlled trial — which is the entire story of BPC-157 in one sentence.
Why this grade — the appraisal in full
Evidence comes from animals, cell cultures or modelling. No human trial has tested this claim. Animal lifespan results do not establish human benefit.
- Human evidence. No human study has tested this claim. Evidence comes from 1 animal study and 0 laboratory studies.
- Translation to humans. Results in animals frequently fail to reproduce in people. A lifespan effect in mice is not evidence of a lifespan effect in humans.
Limitations. The animal literature comes largely from a single research network, and rodent tendon injury is an imperfect model of human injury. No human randomised trial exists on any endpoint.
| Study | Design | Population | Finding |
|---|---|---|---|
| [1]Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopatholo…Joint diseases and related surgery · 2026 · PMID 42542926 | Animal studyAnimal | Size not recorded | Supports the claimRat Achilles tendon injury model; histopathological and biomechanical improvement with BPC-157. |
Improves injury recovery in humans
Insufficient evidenceOutcome measured: Disease outcome — A diagnosed condition or clinical event was measured.
A 2025 systematic review searched for clinical evidence behind BPC-157's growing use in sports medicine and found no published randomised human trial. The confident dosing protocols circulating online are extrapolated from rodent work and anecdote, not from human data.
Why this grade — the appraisal in full
Too little credible research exists to judge the claim either way.
- Strongest study design. Systematic review.
- Human research volume. 1 human study, 0 participants in total.
- What was measured. 1 human study measured a clinical or functional outcome rather than a laboratory marker alone.
- Replication. The supporting result has not been independently replicated in humans.
Limitations. The absence of trials is itself the finding: use in people is running years ahead of any controlled human evidence.
| Study | Design | Population | Finding |
|---|---|---|---|
| [2]Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewHSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025 · PMID 40756949 | Systematic reviewHuman | Size not recorded | Direction not yet appraisedSystematic review of BPC-157 in orthopaedic sports medicine: no randomised controlled human trial identified. |
Human evidence
1 study in people.
- [2]Systematic review
Animal and laboratory evidence
Shown separately, and never used to support a human claim.
- Animal study
Before anything else
Safety and interactions
No controlled human safety data exist. Grey-market peptide vials carry the additional risks of unverified identity, purity and sterility — a concern that applies to injected products in particular. Several sporting bodies prohibit it.
Regulatory and availability. Not licensed as a medicine in the UK or anywhere else. Products sold online as 'research chemicals' are outside medicines regulation entirely — no manufacturing, purity or dosing standards apply to them.
The ledger
Grade history
22 August 2026
First published appraisal of this claim. Study links added: PMID 42542926.
22 August 2026
First published appraisal of this claim. Study links added: PMID 40756949.
Falsifiability
What would change our view
A published randomised controlled human trial on any healing endpoint — none exists. Independent replication of the rodent findings outside the originating research network would also strengthen the preclinical case.
Check everything
Sources
Every citation links to its PubMed record. Bibliographic details are retrieved from PubMed, not written by us.
- [1]Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Biçer O et al.. Joint diseases and related surgery. 2026. PMID 42542926 · doi:10.52312/jdrs.2026.2951
- [2]Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review Vasireddi N et al.. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2025. PMID 40756949 · doi:10.1177/15563316251355551